You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
FISH, PH LIKE ALL PANEL, PEDIATRIC |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB3738 Geisinger Epic ID: 140941 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Bone marrow, whole blood | |
Preferred collection container: |
||
Alternate Collection Container: |
Bone marrow culture transport media
|
|
Specimen required: |
3 mL bone marrow (minimum 1 ml) or 5 mL whole blood ( minimum 3 ml) collected in a sodium heparin (green-top) tube (preferred). Bone marrow collected in transport medium also acceptable. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Do not centrifuge or refrigerate. | |
Transport temperature: |
Room temperature. | |
Specimen stability: |
Transport immediately after collection. Viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject. | |
Rejection criteria: |
Frozen specimens unacceptable. | |
TEST DETAILS |
||
CPT code(s): |
88271 x6, 88275 x3 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Methodology: |
Fluorescence In Situ Hybridization (FISH) |
|
Synonyms: |
Quest code 39035 FISHPH
|
|
Clinical significance: |
FISH, Ph Like ALL Panel - Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as a BCR-ABL1-like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph+) ALL and is suggestive of active kinase signaling. It exibits adverse clinical features, confers poor prognosis and harbors a diverse range of genetic alterations that active cytokine receptors genes and kinase signaling pathways making it amenable to treatment with tyrosine kinase inhibitor (TKI) therapy. This FISH panel has been designed to detect ABL1, ABL2 and PDGFRB rearrangements associated with the BCR-ABL1-like B-ALL (or Ph-like B-ALL) with ABL class fusions. Diagnosis of BCR-ABL1-like B-ALL patients with ABL1, ALB2 and PDGFRB rearrangements, will enable incorporation of TKI much earlier in the course of treatment as well as selection of patients eligible for future therapy trials | |